News
The identification of immune genes that distinguish patients with CRSwNP from healthy controls offers insight into disease ...
Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...
Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 ...
CRSwNP is a chronic disease of the upper airway, driven in part by type 2 inflammation, that obstructs the sinuses and nasal passages. It can lead to breathing difficulties, ...
The approval in adolescent patients was based on evidence from the phase 3 SINUS-24 and SINUS-52 trials (ClinicalTrials.gov Identifier: NCT02912468 and NCT02898454, respectively), which compared ...
Hosted on MSN6mon
China’s NMPA approves GSK’s Nucala for CRSwNP treatmentOften associated with type 2 inflammation, CRSwNP is characterised by high levels of IL-5 in nasal polyp tissue and a tendency for nasal polyps to regrow post-surgery due to persistent inflammation.
Additionally, he said, CRSwNP has a negative impact on quality of life with disturbances in smell, taste and sleep as well as in pain, fatigue and depression. Tezepelumab-ekko ...
Fourth Quarter 2024 and Recent Business Highlights. Completed enrollment in CRSwNP Phase 2 clinical trial: In January 2025, Upstream completed patient enrollment in its Phase 2 multicenter ...
For the CRSwNP indication, the BLA includes data from the ANCHOR-1 (ClinicalTrials.gov Identifier: NCT05274750) and ANCHOR-2 (ClinicalTrials.gov Identifier: NCT05281523) trials, which enrolled ...
CRSwNP affects up to 4% of the general population, with approximately 40% having uncontrolled disease. In Japan, about 200,000 people with chronic sinusitis are subject to surgery due to nasal polyps.
GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results